Annovis Bio ANVS 深 滬
等待開盤 07-23 09:30:00 美东时间
2.58
+0.050
+1.98%
華盛通- 最 高2.63
- 今 開2.60
- 成交量 18.08万股
- 最 低 2.52
- 昨 收 2.53
- 總市值 5027.44万
- 52周最高 10.54
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 1.11
- 委 比 0.00%
- 總股本 1948.62万
- 歷史最高 132.00
- 量 比 0.60
- 振 幅 4.35%
- 歷史最低 1.11
- 每 手 1
- 風險率 3.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) rose sharply in pre-market tradi...
07-22 17:39
Annovis to Attend the AAIC 2025 with Four Poster Presentations
Annovis Bio, a clinical-stage company focusing on neurodegenerative diseases like Alzheimer's and Parkinson's, announced its senior management will participate in the Alzheimer's Association International Conference (AAIC) 2025 in Toronto. The company will present four scientific posters detailing advancements in its Alzheimer’s clinical program and pharmacokinetic studies of its lead drug candidate, buntanetap. Topics include Phase III study des...
06-26 12:00
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
Annovis Bio Approves Board Elections and Auditor Appointment
An update from Annovis Bio ( ($ANVS) ) is now available. On June 17, 2025, Anno...
06-24 05:48
Annovis Bio Announces It Received NYSE Acceptance Letter Granting The Co 18-Month Period To Maintain Listing
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
06-19 18:38
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
Annovis Bio, a company developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's, has received a notification from the NYSE accepting its plan to regain compliance with listing standards regarding market capitalization and stockholders' equity. The company has an 18-month period to meet the requirements and must provide quarterly updates. Its stock will remain listed on the NYSE during this period, contingent on adheren...
06-19 10:30
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
Annovis to Host Webinar and Live Q&A on June 24, 2025
Annovis Bio, a clinical-stage biotech company focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s, will host a live webcast on June 24, 2025, at 4:30 PM EDT. CEO Maria Maccecchini will discuss updates on their pivotal Phase 3 trial for early Alzheimer’s disease, FDA feedback on their Parkinson’s program, and other initiatives. The event includes a presentation and Q&A session, open to shareholders, patients, and interested part...
06-05 12:00
Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $17
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $26 to $17.
05-15 20:14
Annovis Bio Q1 EPS $(0.32) Beats $(0.36) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.36) by 11.11 percent. This is a 55.56 percent increase over losses of $(0.72) per share from the
05-14 04:47
